Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 26;10:5504. doi: 10.1038/s41598-020-62145-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

qPCR validation of differentially-expressed genes and expression in grade II and III gliomas. (A) qPCR quantification of indicated RNAs in foci and in the other part of the tumour (DLGG) in oligodendrogliomas and astrocytomas. Values represent fold change (foci area/non foci area) of indicated RNA expression normalized by RPLP0 quantification. n = 10 tumours. Test = Wilcoxon matched-pairs test. (B) Expression of indicated genes in grade II and grade III gliomas retrieved from the TCGA database. A similar analysis done for all identified genes is presented in Table S3. OII (Oligodendroglioma grade II, 108 patients). OIII (Oligodendroglioma grade III, 76 patients). AII (Astrocytoma grade II, 87 patients). AIII (Astrocytoma grade III, 98 patients). Tests = Kruskal-Wallis with a Dunn post-hoc test.